Travere Therapeutics, Inc.
Clinical trials sponsored by Travere Therapeutics, Inc., explained in plain language.
-
New kidney drug shows promise in FSGS trial
Disease control CompletedThis Phase 3 trial tested whether sparsentan, a drug that blocks two pathways involved in kidney damage, can better protect kidney function than the standard treatment irbesartan in people with focal segmental glomerulosclerosis (FSGS). The study enrolled 371 adults and children …
Phase: PHASE3 • Sponsor: Travere Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New drug cocktail shows promise for slowing kidney disease
Disease control CompletedThis study tested whether adding sparsentan to a standard SGLT2 inhibitor can better protect kidneys in people with IgA nephropathy, a disease that can lead to kidney failure. 48 adults who were already on stable doses of both a blood pressure drug and an SGLT2 inhibitor took spa…
Phase: PHASE2 • Sponsor: Travere Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC